Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


May 07, 2015 4:03 AM ET

Life Sciences Tools and Services

Company Overview of Seahorse Bioscience, Inc.

Company Overview

Seahorse Bioscience, Inc. engages in the design, development, manufacture, and supply of analytical instruments, biomanufacturing systems, and consumable labware products for biological research and drug discovery to the life sciences industry. It offers a line of extracellular flux (XF) instruments, including XFe96 and XFe24 analyzers that measure mitochondrial respiration and glycolysis in cells; XF24-3 analyzer that enables the measurement of the TCA cycle, as well as mitochondrial respiration and glycolysis; and XF prep station that removes growth medium replacing with run medium. The company’s consumable products include XF fluxpaks, cell culture and islet capture microplates, stress te...

16 Esquire Road

North Billerica, MA 01862

United States

Founded in 2000

Phone:

978-671-1600

Fax:

978-671-1611

Key Executives for Seahorse Bioscience, Inc.

Founder, Chairman, Chief Executive Officer and President
Age: 57
Founder and Vice President of Seahorse Labware
Founder and Vice President of Administration & Finance
Founder and Chief Technology Officer
Founder and Vice President of Sales & Marketing
Compensation as of Fiscal Year 2014.

Seahorse Bioscience, Inc. Key Developments

Seahorse Bioscience Introduces XFp Cell Energy Phenotype Test Kit

Seahorse Bioscience introduced the XFp Cell Energy Phenotype Test Kit. The kit enables a unique real-time assay on live cells that determines their baseline metabolic phenotype and potential. This one-hour test measures both the mitochondrial and glycolytic activity of the cells, and compares their baseline values with metabolic activity under stressed conditions, induced by a single injection, to determine the metabolic potential – the cells' ability to respond to an energy demand. This kit has been designed specifically for use with the XFp Extracellular Flux Analyzer. Traditionally, mitochondrial respiration and glycolytic activity is obtained from a number of separate assays, with the comparison performed after the assay completion. The new XFp Cell Energy Phenotype Test is the only method available that can provide a metabolic phenotype with which scientists can make direct, functional comparisons of both metabolic pathways between groups of live cells. With this information cancer researchers can then quickly realize the functional consequences of somatic mutations in terms of metabolic adaptations and reprogramming events that drive tumor malignancies. By simultaneously measuring the relative utilization of the two major energy pathways under both basal and stressed conditions, researchers can now quickly realize the metabolic consequence of genetic changes. The XF Cell Energy Phenotype of tumors containing the Ras oncogenes shows a significant reliance on glycolysis for energy when stressed, revealing a metabolic vulnerability for survival in the hypoxic and acidic environment of a large tumor. The XFp Cell Energy Phenotype Test requires only a small amount of sample to measure the metabolic phenotype and metabolic potential of cells, and the XFp Cell Energy Phenotype Report Generator software automatically calculates the parameters of the test, simplifying data analysis and interpretation. The kit is used with the XFp Analyzer and is ideal for use in pair wise comparisons, as well as with patient-derived and other precious samples. With a better understanding of the connection of physiological traits of cells with genomic and proteomic data, scientists are generating new insights into metabolic function, leading to a greater understanding, and new treatments of disease.

Seahorse Bioscience, Inc. Presents at Jefferies 2013 Global Healthcare Conference, Jun-03-2013 08:00 AM

Seahorse Bioscience, Inc. Presents at Jefferies 2013 Global Healthcare Conference, Jun-03-2013 08:00 AM. Venue: Grand Hyatt Hotel, 109 East 42nd Street at Grand Central, New York, New York, United States. Speakers: Jay Teich, Founder, Chairman, Chief Executive Officer and President.

Similar Private Companies By Industry

Company Name Region
Xenogen Corporation United States
Accel Clinical Services, LLC United States
Qualicaps, Inc. United States
Cylex, Inc. United States
Pacific BioLabs Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Seahorse Bioscience, Inc., please visit www.seahorsebio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.